摘要
目的分析质子泵抑制剂在慢性阻塞性肺疾病伴有反流性食管炎患者治疗中的应用效果。方法选取2022年1月—2023年3月在江苏省泗洪医院接受治疗的86例慢性阻塞性肺疾病(简称慢阻肺)合并反流性食管炎患者作为研究对象,用随机数表法将其分为对照组与观察组,每组43例。对照组行常规治疗,观察组在常规治疗基础上联合质子泵抑制剂(艾司奥美拉唑钠注射液)治疗,比较两组患者干预前后的动脉血气指标水平、反流性食管炎症状发生率、临床疗效等。结果干预前两组患者血液酸碱值(potential of hydrogenpotential of hydrogen,pH)、动脉血氧分压(arterial partial pressure of oxygen,PaO_(2))、二氧化碳分压(partial pressure of carbon dioxide,PaCO_(2))水平对比,差异无统计学意义(P>0.05)。干预后两组患者血液pH值对比,差异无统计学意义(P>0.05);观察组患者PaO_(2)水平升高且高于对照组,PaCO_(2)水平降低且低于对照组,差异有统计学意义(P<0.05)。干预前两组患者反流性食管炎症状对比,差异无统计学意义(P>0.05);观察组干预后食管炎症状的发生率(9.30%)低于对照组,差异有统计学意义(χ^(2)=4.914,P<0.05)。观察组患者临床疗效(97.67%)高于对照组,差异有统计学意义(χ^(2)=4.468,P=0.035)。结论在慢性阻塞性肺疾病合并反流性食管炎患者临床治疗中,予常规抗感染、抗炎、化痰止咳等治疗方式联合艾司奥美拉唑钠等药物的使用能有效改善患者的临床症状,具有显著疗效体现。
Objective To analyze the effect of proton pump inhibitors in the treatment of chronic obstructive pulmonary disease with reflux esophagitis.Methods A total of 86 patients with chronic obstructive pulmonary disease(COPD)complicated with reflux esophagitis treated in Sihong Hospital of Jiangsu Province from January 2022 to March 2023 were selected as the study objects.The patients were divided into control group and observation group by the method of random number table,with 43 cases in each group.The control group was treated with routine treatment,and the observation group was treated with proton pump inhibitor(esomeprazole sodium injection)on the basis of routine treatment.The level of arterial blood gas index,incidence of reflux esophageal inflammation and clinical efficacy were compared between the two groups before and after intervention.Results Before intervention,potential of hydrogenpotential of hydrogen(pH),arterial partial pressure of oxygen(PaO_(2)),partial pressure of carbon dioxide(PaCO_(2))level of the two group had no statistically significant difference(P>0.05).After intervention,there was no significant difference in pH level between the two groups(P>0.05).The level of PaO_(2) in the observation group increased and was higher than that in the control group,and the level of PaCO_(2) decreased and was lower than that in the control group,and the differences were statistically significant(P<0.05).Before intervention,there was no statistically significant difference in reflux esophagitis between the two groups(P>0.05).The incidence of esophageal inflammation symptoms in the observation group(9.30%)was lower than that in the control group,and the difference was statistically significant(χ^(2)=4.914,P<0.05).The clinical efficacy of the observation group(97.67%)was higher than that of the control group,and the difference was statistically significant(χ^(2)=4.468,P=0.035).Conclusion In the clinical treatment of patients with chronic obstructive pulmonary disease accompanied by acute aggravation and reflux esophagitis,the use of conventional anti-infection,anti-inflammation,phlegm-relieving cough and other treatments combined with esomeprazole sodium and other drugs can effectively improve the clinical symptoms of patients,and has a significant effect.
作者
李献
LI Xian(Department of Respiratory Medicine,Sihong Hospital,Sihong,Jiangsu Province,223900 China)
出处
《系统医学》
2023年第19期78-80,92,共4页
Systems Medicine
关键词
慢性阻塞性肺病
反流性食管炎
质子泵抑制剂
Chronic obstructive pulmonary disease
Reflux esophagitis
Proton pump inhibitor
